MADRID, June 24, 2017 /PRNewswire/ --
Providing the right treatment in time for patients with
hematologic malignancies: that is the ambition of the
HARMONY Alliance, European Network of Excellence
in Hematology and Big Data. HARMONY will make use of today's Big
Data technologies in order to accelerate more efficient drug
development, regulatory evaluation, access appraisal and treatment
strategies.
(Logo:
http://mma.prnewswire.com/media/524821/EHA_Logo.jpg )
The HARMONY Alliance was launched in January 2017 and is funded through the
Innovative Medicines Initiative (IMI),
Europe's largest public-private
initiative aiming to speed up the development of better and safer
medicines for patients.
Tomorrow, June 24,
at the 22nd Congress of the European Hematology
Association, HARMONY will present its goals and
objectives at an Introductory and Onboarding Session.
Presenting the first two bench-to-bedside projects
At the June 24 session, HARMONY will
be presenting its first two bench-to-bedside research projects. One
is the proof-of-concept study in acute myeloid leukemia, 'Big Data
for Better AML Outcomes', focusing on the impact of genomics and
value of intensive treatment approaches in MDS/AML. The second
project,'Prognostic factors of treatment with hypomethylating
agents (HMA) in higher risks MDS and advances CMML'. This project
focuses on the impact of genomics and value of intensive treatment
approaches in MDS/AML.
Harmony in Hematology
The Harmony Alliance consists of 51 partners and brings together
key stakeholders from a broad spectrum of disciplines from 11
European countries. Expertise is drawn from academic institutions,
national clinical disease networks, European organizations, patient
advocacy groups, clinicians, and pharmaceutical companies, as well
as regulatory agencies, experts in economics and ethics, and
information and technology (ICT) specialists.
HARMONY has received funding from IMI 2 Joint Undertaking and is
listed under grant agreement No. 116026.
This Joint Undertaking receives support from the European
Union's Horizon 2020 research and innovation programme and the
European Federation of Pharmaceutical Industries and Associations
(EFPIA).
IMI supports collaborative research projects and builds networks
of industrial and academic experts in order
to boost pharmaceutical innovation in Europe.
More information: http://www.harmony-alliance.eu